No Data
No Data
Unusual Options Activity: DG, ROIV and Others Attract Market Bets, DG V/OI Ratio Reaches 100.0
Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus
Unusual Options Activity: ADMA, MA and Others Attract Market Bets, ADMA V/OI Ratio Reaches 406.2
Cantor Fitzgerald Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $25
Earnings Preview: ADMA to Report Financial Results Post-market on May 07
ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025